Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions.
press release announcing its financial results for the quarter
ended March 31, 2017. The information in this Item 2.02 of Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities under
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference.
|
No.
|
Description
|
|
99.1
|
Press Release titled Cleveland BioLabs Reports First
Quarter 2017 Financial Results and Development Progress, dated May 15, 2017 |
About Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5. Cleveland BioLabs, Inc. (NASDAQ:CBLI) Recent Trading Information
Cleveland BioLabs, Inc. (NASDAQ:CBLI) closed its last trading session up +0.31 at 3.47 with 532,083 shares trading hands.
